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INTRODUCTION 
Any biomedical product to be distributed commercially 
must undergo a development and assessment process 
before being placed on the market. The appropriate level 
of scrutiny and rigorous testing before commercialization 
is of paramount importance, due to the risk of potential 
harm. In most cases, especially for products that fall into 
the higher risk classes, the producing company must 
demonstrate the efficacy of the product in healing or 
alleviating the effects of a disease or disability, as well as 
an acceptable safety profile, before any widespread use. 
Today, the only conclusive (and accepted) way to ensure 
the safety and efficacy of a biomedical product is to test it 
on living organisms, first on animals (preclinical 
evaluation) and then on humans (clinical evaluation).  
The preclinical evaluation process represents an essential 
step in the development of any potential biomedical 
product. It is the means by which the fundamental basis 
for how a product might work is evaluated and, 
hopefully, confirmed. However, due to the hugely 
complex nature of human diseases, the significant 
differences between individuals, and the inevitable 
variability in how a treatment is administered, it is not 
unusual for a product to perform exceptionally well in 
tightly controlled laboratory studies, but show some 
serious problems during clinical trials. According to the 
Tufts Center for the Study of Drug Development,2 the 
development of a new pharmaceutical product, and its 
introduction into the market, is estimated to exceed 
US$2.5 billion, over 75% of which is spent on in vivo 
studies, whether on animals or on humans. Every time a 
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product fails late in the process, for example at the end of 
phase II or even in phase III trials, companies suffer a 
huge loss.  
Whilst clinical trials may tell us that a product is unsafe 
or ineffective, they rarely tell us why, or suggest how to 
improve it. As such, a product that fails during clinical 
trials may simply be abandoned, even if a small 
modification might solve the problem, resulting in the 
potential creDWLRQ RI DQ µDOO-or-QRWKLQJ¶ mind-set in the 
biomedical industry.  
Such a paradigm stifles innovation, decreasing the 
number of truly original biomedical products presented to 
the market every year, and at the same time increasing the 
cost of development (which, paradoxically, further 
increases the risk as the pressure to contain such costs 
increases). As a result, it is also becoming increasingly 
difficult for companies to undertake the development of 
new products targeting rare conditions, either because the 
associated costs cannot be justified against the limited 
return on investment, or because the resulting sale prices 
would be so high as to pose a challenge for universal 
healthcare systems.  
The biomedical industry is not the only sector that deals 
with highly complex and potentially critical systems. In 
other industrial sectors, such as aerospace or nuclear 
industries, computer modeling and simulation is used 
extensively during both product development and 
assessment to overcome similar safety problems with 
mission-critical products. Can the same approach be used 
for biomedical products? In addition to traditional in vitro 
and in vivo studies, might we adopt a third way for 
developing and testing biomedical products by making 
XVHRIWKLVµLQVLOLFR¶technology? 
In 1955, Solomon and Gold published a three 
compartment model of potassium transport in human 
erythrocytes.2 This appears to be the first paper indexed 
by Index Medicus (now PubMed) with the keywords 
physiology and computer. From that first study until the 
late 1980s, most computer models aimed to capture the 
basic mechanisms underlying physiological or 
pathological processes in mathematical form, without 
intending to make quantitatively accurate predictions.  In 
the 1990s, the development of stochastic modeling and 
increased computational powers enabled the development 
of population-specific models that aimed to predict the 
average value of specific quantities over a population.3-10  
In the early 2000s, the computational ecology community 
started to debate the virtues of individual-based models 
for population ecology.11 Soon after, in silico medicine 
research also began to use the first patient-specific 
models12-17 and some analysts started to suggest that such 
approaches could be useful in the development of new 
medical products.18  
In 2007, a group of experts published ³Veeding the 
EuroPhysiome: a roadmap to the virtual physiological 
KXPDQ´. They presented a scenario where imaging and 
sensing technologies were used to generate quantitative 
information about the biology, physiology, and pathology 
of a patient at different scales of space and time. This 
information would then be used as the input for 
multiscale computer models encapsulating all the 
knowledge available for a given disease process, in order 
to produce patient-specific predictions for diagnosis, 
prognosis, and treatment planning. Since then, dozens of 
single research teams and consortia around the world 
have developed a whole set of new technologies and 
methods, initiated with a similar perspective to that 
original research roadmap. While the vision of the Virtual 
Physiological Human (VPH) is not yet entirely realised, 
VPH technologies are being assessed clinically in a 
number of practical applications and preliminary results 
suggest important improvements over current standards 
of care. In some of these projects it has been necessary to 
simulate the treatment in addition to the pathophysiology 
in order to predict how a patient would respond to a 
particular treatment option.  In the RT3S project, the 
deployment and the fatigue cycling of peripheral vascular 
stenting was modeled.19 The VPHOP project included a 
model of the effect of vertebroplasty in adjacent 
vertebrae.20 Some other projects have gone even further, 
for example, the PreDICT project, which used VPH 
models to assess the cardio-toxicity of new drugs.21 
Another project used an in silico acute stroke model to 
explore why hundreds of compounds that have been 
shown efficacious in rodent models failed in phase II or 
III clinical trials: the ratio of astrocytes over neurons, 
which is quite different in human brains and in rodents, 
was suggested as the cause.22 One of the essential traits of 
the VPH approach is the recognition that there is no 
preferential scale, and each problem should be tackled 
starting from the space-time scale where the process is 
observed (middle-out approach).  
Of course this is not the only approach that was pursued. 
Many research teams worldwide adopted a bottom-up 
process, in an attempt to translate the systems biology 
approach into clinical practice.23-25 Some envisaged a 
future model of Predictive, Preventive, Personalized and 
Participatory medicine (P4) based on the translation of 
systems biology, or as it has later become known, 
systems medicine.26 While this approach holds the 
potential for huge impact, especially in relation to the 
discovery of new pharmaceutical compounds, in many 
cases there are knowledge gaps that make the clinical 
application difficult.27 One particularly important 
limitation is the ability to model cell-tissue interactions, 
as was stressed in the 2009 workshop jointly organised 
by the United States Environmental Protection Agency 
and the European Commission . Some authors have tried 
to bridge this with phenomenological models, such as the 
Effect Model Law.28,29 All these research activities 
embraced a scenario in which VPH models could be used 
not to enhance the clinical management of patients 
affected by particularly difficult pathologies, but rather to 
design and assess biomedical products. In 2011, the VPH 
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,QVWLWXWH LQWURGXFHG WKH WHUP µLQ VLOLFR FOLQLFDO WULDOV¶ 
(ISCT) to describe this type of activity.  
The biomedical industry already uses computer modeling 
and simulation in the development, and to a lesser extent 
in the assessment process, but such use is currently 
limited: 
a) Medical device companies use it mostly in the design 
phase and what is modeled is primarily the device (where 
conventional engineering modeling techniques can be 
used), whereas the host organism is mostly reduced to 
some boundary / environmental conditions (i.e. the 
musculoskeletal system is reduced to the force applied on 
the joint replacement being designed).30,31 
b) Molecular dynamics simulations are used to explore 
the fundamental chemistry of new pharmaceutical 
compounds, for example in their interaction with the 
carrier.32 
c) Population pharmacokinetics are extensively used to 
investigate the absorption, distribution, metabolism, and 
excretion of new drugs.33 
d) More recently, systems biology modelling has been 
used in discovery, and relation to specific risks such as 
cardiotoxicity.34 
Most of these uses are very early in the development 
cycle, around design/discovery activities, so they make 
very little impact on the cost of innovation, which is 
dominated by the trials costs.  What industry needs are in 
silico technologies that help to reduce, refine or partially 
replace animal and human experimentation. This 
terminology, normally used in the context of animal 
experimentation reduction, can be applied also to humans 
with the following terminological clarification, to be used 
hereinafter: 
a) Reduce means the reduction of the number of animals 
or humans involved in the experimentation, and/or the 
duration of such involvement. 
b) Refine means the reduction of the suffering or of 
simply the risks the experimentation involves. However, 
here we will consider the reduction of suffering and risk 
in relation to how effectively the trial fulfills its purpose; 
that is, how accurately the trial predicts the efficacy and 
the safety of the new product once it becomes widely 
used.  So, refinement can be achieved by reducing the 
suffering or risks associated with the trial while its 
usefulness remains unchanged, or improving its 
usefulness while keeping the suffering/risk unchanged. 
c) Replacement refers to the possibility of avoiding the 
trial entirely.  While this is a theoretical option for animal 
trials,35 it is not for human trials.  Thus, we use the 
expression partial replacement.  
Developing in silico technologies to reduce, refine and 
partially replace in vivo experimentation requires 
overcoming barriers of three kinds: knowledge, as we to 
some extent still lack the fundamental and technological 
knowledge required; reliability, enough to entrust part of 
a fundamentally mission-critical process to a new 
technology; and adoption, which involves changes in 
business practice that the adoption of disruptive 
technologies always involve. There are three actors 
central to the development of in silico technologies to 
reduce, refine and partially replace in vivo 
experimentation: the academic research community that 
should overcome the knowledge barriers, the regulators 
who should address the reliability barriers, and industry 
that should address the adoption barriers.  But the 
industrial providers of modeling and simulation 
technologies largely do not work around biomedical 
products, and the industries developing biomedical 
products largely do not work with simulation 
technologies; researchers need industrial guidance to 
orient their efforts where is necessary, and regulators 
cannot develop reliability in silico technologies without 
the support of researchers and industry experts.  Before 
any solid innovation in this area can appear, we need to 
create a community of practice, where all these 
stakeholders discuss and network, in order to produce a 
research and technological development roadmap to 
orient effectively all efforts. 
The process 
The European Commission funded the Avicenna support 
action with the specific purpose to elaborate a research 
and technological research roadmap for the area referred 
as In Silico Clinical Trials (ISCT).  The action ran from 
October 2013 until September 2015; the process the 
Avicenna consortium used to develop this roadmap can 
be summarised in three steps.  
Form a community of practice; 
x Capture the consensus of the experts within this 
community. 
x Consolidate all the inputs in a final draft version 
of the roadmap. 
x Publicly validate the roadmap with all 
stakeholders.  
The community of practice was formed starting from a 
nucleus of roughly 200 experts who expressed 
preliminary interest for the Avicenna action, which 
expanded during the duration of the consensus process to 
577 experts.  Over the 24 months of activity we contacted 
nearly 5,000 experts worldwide, informing them of the 
Avicenna action. Table 1 details the composition of this 
community of practice in terms of expertise.  Researchers 
UHSUHVHQWHG  RI WKH H[SHUWV¶ SDQHO IROORZHG E\
producers of biomedical products (26%), providers of 
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clinical trial services (25%), regulators (12%), and others 
(8%).  In terms of nationality 69% were from Europe, 
22% from USA, and 10% from other countries.  Within 
Europe, UK was the most represented state (17%), 
followed by Italy (12%), France, Germany and Spain 
(7%); overall 37 countries were represented, including 25 
of the 28 EU member states.   Most experts participated 
in the consensus process remotely, but 105 of them 
attended at least one of the five events the Avicenna 
action organised in Rome, Brussels, Lyon, and 
Barcelona.
 
Table 1: Number of experts engaged in the Avicenna consensus process, subdivided by their clusters and expertise. 
 
  Consortium Consumers Producers Providers Regulatory Research Spenders 
Consortium 17 
      
Patient's Orgs 
 
6 
     Charity 
 
6 
     
Medical Devices 
  
78 
    
Large Biopharma 
  
65 
    Small Biopharma 
  
9 
    
ISCT 
   
42 
   Software & hardware 
   
39 
   Consultants 
   
26 
   
Research Hospitals 
   
21 
   CRO 
   
9 
   
Trade organisation 
   
6 
   
Data Banks 
   
3 
   
National 
    
53 
  Supranational 
    
14 
  
Math, physics, and engineering sciences 
   
56 
 Computational biomedicine 
     
55 
 
Medical Research 
     
30 
 
social and economical sciences 
     
15 
 
Biology, systems biology, and biochemistry 
     
12 
 
Funders 
      
12 
Banking & insurance 
      
3 
Total x each cluster 17 12 152 146 67 168 15 
 
To those experts who agreed to get involved in the 
process, we offered an opt-out mechanism that allowed 
them the option of removing themselves at any time if 
they did not agree with the consensus process. Very few 
took this option during the process and the numbers 
reported here refer to those who agreed to sign the final 
roadmap, and whose names are listed in its appendix. 
The consensus process over such a wide and 
heterogeneous community required a specialised 
approach. In 2005, Thomas Schelling received the Nobel 
Prize in Economics for having enhanced our 
understanding of conflict and cooperation through game-
theory analysis. In particular, he developed the concept of 
a focal point (known as a Schelling point), which is the 
solution to an opportunity most people will select when 
sub-optimal communication hinders consensus building. 
From this, and two related behavioural sciences, 
Alignment Optimisation (AO) has emerged as a 
management science, providing a crowd-sourcing 
knowledge discovery process that efficiently yields 
endorsed, coordinated actions for a group with a shared 
purpose. AO, in the on-line implementation provided by 
SchellingPoint, was selected as the primary method for 
crowd-sourcing knowledge from participants in the 
Avicenna process, based on previous experience of one 
of the partners using the technology in a similar context 
relating to the application of systems biology to drug 
discovery and development.36 Overall 214 experts 
actively participated in the AO consensus process.  In 
addition, five physical meetings where organised; in four 
the participation was capped to 50 delegates to ensure an 
effective interactions.  The fifth was a public event aimed 
to validate broadly the final draft of the roadmap. 
Initially the roadmap was intended to be a single booklet 
to be read in its entirety by all stakeholders. Thus, we 
organised a first tentative index for such a document, and 
started to populate it with the inputs generated by the AO 
process. At each cycle a stand-alone document or 
µSRVLWLRQSDSHU¶ ZDVGHULYHG IURP WKH FXUUHQW GUDIW DQG
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circulated to all experts in advance of the meeting. 
Written comments, as well as all the inputs collected 
during the meeting were combined with the outputs of the 
following AO cycle to compose the next draft. After the 
third event in October 2014, the complexity of the 
roadmap started to increase exponentially. New sections 
were added, some of which were relevant only to some 
stakeholders. During the first review meeting with the 
European Commission, the reviewers identified the need 
for a structured approach, a sort of reading guide that 
would point each category of stakeholder to read only 
those chapters that were relevant to them. As a result of 
these reflections and after the fourth event, the roadmap 
was completely re-organised. The document was divided 
into 11 chapters, each one designed to be readable either 
as a stand-alone document, or together with the others. 
We developed a reading guide for different categories of 
readers to ensure an effective comprehension of the 
roadmap. After this reorganisation, a draft version of each 
chapter was posted as an unformatted google doc open 
for editing to anyone with the link. The links were sent to 
all members of the avicenna community of practice, 
giving everyone the opportunity to edit the content of the 
entire roadmap. In parallel, a Mendeley bibliographic 
database, also public, was made available for everyone to 
add relevant papers to be cited in the roadmap. After this 
revision round, the text was collected, and formatted into 
Microsoft Word documents, with the inclusion of figures 
and bibliographic references. The resulting document was 
posted on the public avicenna website and all the 
available communication channels were used to invite 
our experts, as well as any other interested parties to 
revise and comment on these documents. The final draft 
roadmap was circulated in advance of the final Avicenna 
meeting, where it was discussed extensively. All 
comments collected online or during Event Five were 
consolidated into the final version of the roadmap, which 
can be freely downloaded in PDF format from Research 
Gate. The list of experts involved in the consensus 
process can be found in Annex 1 of the roadmap.1 
The full roadmap, with its 116 pages is massive 
document.  Here we will try to summarise some of the 
key elements: the definition of ISCT, the use cases that 
emerged, the challenges that remain to be met for a full 
adoption, and some of the key recommendations to 
funders and policy makers. 
Definition of ISCT 
A lot of time was spent in discussing a definition of in 
silico clinical trials that was broad enough to cover all 
relevant use cases, but specific enough to be informative 
and useful. Consensus was reached on the following:  
The use of individualised computer simulation in the 
development or regulatory evaluation of a medicinal 
product, medical device, or medical intervention. It is a 
VXEGRPDLQ RI µLQ VLOLFR PHGLFLQH¶ WKH GLVFLSOLQH WKDW
encompasses the use of individualised computer 
simulations in all aspects of the prevention, diagnosis, 
prognostic assessment, and treatment of disease.   
Two elements are worthy of further explanation: firstly, 
the reference to individualised computer simulations and, 
secondly, references to biomedical products in general. 
The choice of the word individualised in place of the 
more popular personalised reflects a majority view 
amongst our experts that the latter is primarily used to 
indicate stratification by genetic information, whereas 
here we refer to the use of all available information 
including genomics, post-genomics, metabolomics, 
microbiomics, medical imaging, biomedical 
instrumentation (including implanted, wearable, or 
environmental sensors), self-reported, and clinical data.  
The roadmap identifies three levels of individualisation, 
which are defined in terms of how the predictive accuracy 
of the model is quantified: 
Level 1: The model intends to represent one generic 
individual of the reference population. Its predictive 
accuracy is measured by comparing the model 
predictions to the range of observed values in the 
reference population. 
Level 2: The model intends to represent an average 
individual of the reference population. Its predictive 
accuracy is measured by comparing the model 
predictions to the central properties (average, median, 
etc.) of distribution of values observed in the reference 
populations. 
Level 3: The model intends to represent each individual 
of the reference population. Its predictive accuracy is 
measured by comparing the predicted values to the 
observed values for each individual in the reference 
population. 
Regarding the decision to refer generically to biomedical 
products, in spite of the profound difference that exists 
between pharmaceutical products and medical devices, 
our experts agreed that there are lessons to be learnt 
across these industrial sectors, although many aspects are 
specific. As a result the roadmap includes in depth 
sections specifically for drugs and devices, and others 
that are more general. 
In silico clinical trials: use cases current and future 
At the cost of oversimplifying, we can reduce the 
development and assessment cycle of a biomedical 
product into three macro-phases: design/discovery, pre-
clinical assessment, clinical assessment; in silico 
technologies have the potential to impact positively on all 
three. While the Avicenna roadmap addresses all three 
phases, here we will focus only on the potential use of the 
use of individualised computer models in the reduction, 
refinement, and partial replacement of animal and human 
experimentation. 
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A first use case that emerged in the consensus process is 
that where individualised computer models are used in 
combination with imaging and sensing to produce 
surrogate measurements for biomarkers that cannot be 
directly measured non-invasively, but whose longitudinal 
evolution is highly informative of the efficacy or of the 
safety of the product being tested.  This can be applied 
both in pre-clinical studies on animals, and in clinical 
studies on humans. For example in vivo computed 
tomography data can inform individualised finite element 
models that accurately predict non-invasively the changes 
in bone strength or joint stresses in longitudinal studies, 
both in mice,37-40 and in humans.41-45 This use case is 
related to refinement, in the definition we provided 
above, as modelling can replace invasive measurements 
that involve suffering in animals, and increased risk in 
humans; or improving the usefulness of the in vivo trials 
by making measurable a more significant biomarker, 
while retaining the same level of risk/suffering. 
A second is the use of individualised models to reduce 
the number of animals or humans involved in the 
experimentation, and/or the duration of such 
involvement. A first example is related to the previous 
use case: when a surrogate measurement considerably 
improves the experimental reproducibility of the in vivo 
study, the numbers required for statistical significance is 
reduced.  A second example is when the endpoint can be 
surrogated by individualised model prediction: for 
example a clinical trial of a new bone drug aimed to 
preserve the mechanical strength of bones as a means to 
avoid bone fractures could replace the fracture endpoint, 
with a bone strength endpoint, which is highly predictive 
of the risk of bone fracture.43 
A third is where individualised models can partially 
replace animals or humans in a trial.  The USA Food and 
Drug Administration (FDA) has already approved the 
complete replacement of experiments on dogs with a 
diabetes type I simulator 35 for the de-risking of new 
artificial pancreas technologies. In silico tools are being 
considered as possible replacements for animal 
experimentation in the pre-clinical assessment of 
cardiotoxicity.46,47 For humans the argument is more 
complex as all experts exclude the complete replacement 
of human clinical trials for high-risk products, in the 
foreseeable future. However, a possible scenario is that of 
using individualised models to generate virtual patients 
with specific characteristics to supplement clinical trials 
on real patients.  One possible approach is to design the 
trial using a Bayesian approach, and to treat the 
predictions from the virtual patients as an a priori 
probability.48  
A fourth somehow related use case refers to situations 
where the de-risking with conventional clinical trials is 
impossible, or unsustainable.  Osteogenesis imperfecta 
(OI) has a prevalence of 1/20,000 new born, which makes 
roughly 200 children per year in the USA.  A phase III 
clinical trial that would involve 2000 OI patients of the 
same age would be impossible. But the problem is 
broader than this; if a severe complication with a new 
drug appears only in patients with a combination of traits 
that appear in the general population with a probability of 
one in 10,000, such a complication could never appear in 
any clinical trial. However, the severity of the 
complication might make it still a concern, even with 
such low probability when the product is commercialised.  
This problem is particularly acute in medical devices, 
where it is not uncommon to obtain pre-market approval 
on the basis of trials involving only one or two hundred 
patients.  In all these cases in silico-augmented clinical 
trials can be designed to use virtual patients to explore 
less common phenotypes (anatomical, functional, 
metabolic, or genetic) that by random sampling would be 
quite difficult to recruit. Of course this can in principle be 
done also experimentally, but creating a virtual patient 
with a BMI >90 is surely much easier than recruiting one, 
for example.  
The challenges 
As we wrote in the introduction, developing in silico 
technologies to reduce, refine and partially replace in 
vivo experimentation requires overcoming knowledge, 
reliability, and adoption barriers.  The Avicenna roadmap 
extensively analyses all these barriers, developing a broad 
research and technological roadmap that research-funding 
agencies should use to orient their investments in this 
area. Here, again for brevity, we mention only a few 
challenges that were considered by our experts to be of 
greater importance. 
Reducing, refining, and partially replacing clinical 
trials 
Further research is required on the use of in silico 
technologies for the reduction, refinement, and partial re 
placement of product trials on animals and on humans. 
Research is required into methods through which subject-
specific models can provide more reproducible outcome 
measures, reducing the size of the animal or human 
cohorts required for statistical significance. Trial 
refinement using subject-specific models replacing where 
possiEOHDQLPDOV¶YLYLVHFWLRQDQGUHGXFLQJULVNLQKXPDQ
trials should also be examined. Additionally, studies are 
required to examine the ways in which subject-specific 
models might partially replace trials, by augmenting or 
complementing the in vivo cases with in silico versions. 
Finally, research should be conducted into how subject-
specific models can transform product trials targeting 
paediatric and rare diseases. 
We also recommend research towards the development 
and validation of in silico models that assist in scaling 
and extrapolating observations from in vitro and in vivo 
studies on animals into possible outcomes in vivo in 
humans. 
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The physiological envelope, the deployment envelope 
The entire range of possible values a physiological 
parameter can assume in a given subject during daily life 
is referred as the physiological envelope.49 The Avicenna 
experts reached ample consensus that for the successful 
adoption of in silico clinical trial technologies, it is 
essential these technologies are also capable of 
individualising behavioural aspects such as nutrition, 
physical activity, consumption of alcohol or recreational 
drugs, constipation, therapeutic compliance, etc.  In other 
words it is essential to develop the methods and the 
technologies that allow the definition of a reliable 
physiological envelope for each physiological biomarker 
that characterises those behaviours that could in any way 
interfere or affect the biomedical product under 
assessment. For products that are deployed (i.e. surgically 
implanted medical devices), a similar reason applies to 
the deployment envelop, i.e. the quantification of the 
reproducibility of the deployment/implantation of 
specific classes of biomedical products. 
From validation to confidence 
Another grand challenge for in silico clinical trials is the 
establishment of sufficient confidence, among 
practitioners and regulators.  This is usually reduced to 
the specific aspects of verification, validation and 
uncertainty quantification as formulated for models used 
in other industrial contexts.  But there is a need for a 
framework that specifically addresses the needs of the 
biomedical industry. In January 2014 the FDA produced 
GUDIW JXLGDQFH IRU VWDII DQG LQGXVWU\ RQ ³5HSRUWLQJ RI
Computational Modeling Studies in Medical Device 
Submissions.  Then they contributed to the establishment, 
within the American Society of Mechanical Engineering 
standardisation committees, of a Verification and 
Validation V and V-40 sub-committee charged of 
developing a new technical standard for the verification 
and validation in computational modelling of medical 
devices.   
But the problem is broader, and involves three major 
barriers:  
x Cultural resistance from the specialist 
workforce, mostly formed by biologists, 
pharmacologists, and medical practitioners with 
a limited background in mathematics and 
physics.  
x The resistance of regulators, who historically 
have not accepted evidence obtained in silico for 
the certification process of new biomedical 
products, especially those in higher risk 
categories; and  
x The inherent complexity associated with the 
accurate, quantitative modelling of living 
organisms. There are signals that suggest this 
situation is changing, although probably not as 
quickly as it could.   
A necessary step is the activation of research projects 
aimed at demonstrating the reliability of ISCT, for 
example by comparing retrospectively the results 
obtained in silico with those obtained in vivo. 
We also recommend methodological research on 
frameworks for the assessment of the predictive accuracy 
of subject-specific models when the quantities to be 
predicted can be observed experimentally only with large 
uncertainty. 
Automation for high-throughput 
Currently the vast majority of subject-specific modelling 
techniques require significant amounts of manual work 
by an extremely specialised workforce. While this is 
acceptable in research settings, if these methods are to be 
adopted by the biomedical industry, the development of 
new high-throughput methods automating subject-
specific modelling, including treatment simulation, is 
needed.  This involves the large-scale execution of 
complex personalised simulations on substantial numbers 
of cases (>1000), technologies that automate the 
replication of the ISCT if the product is modified, and 
visual analytics technologies to explore these data sets 
effectively, including interactive visualisation 
technologies that facilitate communication with non-
technical members of the product team. 
Recommendations 
The Avicenna roadmap includes 36 specific 
recommendations for various stakeholders, including 
educators, researchers, funders, policy makers, providers 
of ISCT technologies, etc. Here we report only a few, 
relevant for producers (i.e. biomedical industry), and 
regulators. 
R23 - We recommend that the producers of biomedical 
products contribute to precompetitive collaborations with 
the aim of: 
a. Establishing an in silico assessment framework for 
each family of devices, which investigates all relevant 
failure modes for that device. This will enable research 
groups to extend the framework with refined/alternative 
predictors for the various failure modes. 
b. Evaluating retrospectively a number of biomedical 
products, both successful and unsuccessful, for which the 
clinical outcome is well known, in order to build 
confidence in the methods. 
c. Running double-blind ISCT in parallel with existing in 
vivo clinical trials, comparing the current best practice 
with modified approaches that include modelling and 
simulation. Precedence should be given to critical areas 
such as paediatric and rare diseases, drug retargeting, etc. 
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R29 - We recommend that regulatory bodies across the 
world embrace the innovation offered by in silico 
technologies and, in collaboration with academic and 
industrial experts, develop the framework of standards, 
protocols, and shared resources required to evaluate the 
safety and the efficacy of biomedical products using 
ISCT technologies. 
R30 - We recommend that regulators consider also 
regulating in silico services to be used for the assessment 
of biomedical products as medical devices in their own 
right (i.e. software as a medical device). 
R31 - We recommend that all European regulators follow 
the approach used by the USA Food and Drug 
Administration, which has recognised the strategic 
potential of in silico technologies, such as with the 
Medical Device Development Tool process and is 
working closely and publicly with academia and industry 
to develop standards and protocols that ensure their 
effective and safe adoption. We endorse the formation of 
the Medical Devices Innovation Consortium, as a vehicle 
for such pre-competitive collaborative efforts. 
R32 - As the Avicenna consensus process has 
demonstrated, in a globalised economy the discourse on 
ISCT must develop worldwide; thus, we recommend that 
all agencies remove as many barriers as possible, and 
actively support pre-competitive research and 
technological development across countries and 
continents. 
R35 - We recommend that the Avicenna Community of 
Practice, and in particular the industrial and academic 
stakeholders, form the Avicenna Alliance for Predictive 
Medicine, to coordinate and implement public and 
privately funded research on this topic, and to develop 
policy recommendations designed to overcome all 
barriers that slow or limit the adoption of ISCT 
technologies. This alliance should work closely with the 
Innovative Medicines Initiative public-private partnership 
in order to avoid duplication and favour synergy. 
In Silico Clinical Trials can truly transform the 
biomedical industry, and they represent the best hope for 
the long-term sustainability of universal models of 
healthcare. The time is now, the challenge is huge; and 
only if we all work together will we succeed. 
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